Novartis AG
XHAM:NOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novartis AG
XHAM:NOT
|
CH |
|
H
|
HaTay Pharmaceutical JSC
VN:DHT
|
VN |
|
Erie Indemnity Co
F:EI2
|
US |
Intrinsic Value
The intrinsic value of 
Novartis AG (NOT) under the Base Case is 55.18 EUR per share.
Compared with the current market price of 80.19 EUR, the stock appears
Overvalued by 31% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Novartis Does
Novartis AG is a global drugmaker that discovers, develops, manufactures, and sells prescription medicines. Its main products are branded treatments for serious illnesses, including cancer, immune diseases, heart and kidney conditions, eye disease, and some rare disorders. It does not sell everyday consumer health products; its business is centered on medicines that doctors prescribe to patients.
- Headquarters
- Switzerland CH
- Employees
- 75 267
- IPO date
- May 7, 2001
Novartis has no economic moat
Patent protection keeps copies of individual Novartis medicines out temporarily, but it does not permanently prevent competitors from taking sales. Generic competition affecting medicines such as Entresto and Tasigna shows why successful products alone do not ensure lasting protection across the company.
Read the full moat analysis
Revenue & Expenses Breakdown
Novartis AG
Earnings Waterfall
Novartis AG
The intrinsic value for Novartis AG (NOT) under the Base Case is 55.18 EUR.
Compared with the current market price of 80.19 EUR, the stock appears Overvalued by 31% .